amphastar
pharmaceuticals
receives
fda
approval
atropine
sulfate
injection
rancho
cucamonga
globe
newswire
amphastar
pharmaceuticals
nasdaq
amph
announced
food
drug
administration
fda
approved
company
abbreviated
new
drug
application
anda
atropine
sulfate
injection
ml
ml
prefilled
syringe
system
past
years
company
sold
marketed
product
grandfather
exception
termed
unapproved
fda
prescription
drug
program
net
revenues
company
atropine
sulfate
injection
year
ended
december
million
amphastar
ceo
president
jack
zhang
commented
fda
approval
atropine
sulfate
product
product
often
agency
drug
shortage
list
offers
opportunity
ensure
quality
products
produced
highest
standard
highlights
amphastar
manufacturing
capacity
fulfill
market
pipeline
information
company
currently
four
andas
filed
fda
targeting
products
market
size
approximately
billion
three
biosimilar
products
development
targeting
products
market
size
approximately
billion
nine
generic
products
development
targeting
products
market
size
approximately
billion
market
information
based
iqvia
data
months
ended
june
company
developing
multiple
proprietary
pipeline
products
injectable
intranasal
dosage
forms
including
new
drug
application
intranasal
naloxone
amphastar
chinese
subsidiary
anp
currently
drug
master
files
dmf
file
fda
developing
several
additional
dmfs
company
information
amphastar
specialty
pharmaceutical
company
focuses
primarily
developing
manufacturing
marketing
selling
generic
proprietary
injectable
inhalation
intranasal
products
additionally
company
sells
insulin
api
products
company
finished
products
used
hospital
urgent
care
clinical
settings
primarily
contracted
distributed
group
purchasing
organizations
drug
wholesalers
information
resources
available
amphastar
logo
trademarks
service
marks
amphastar
including
limited
primatene
property
amphastar
statements
statements
press
release
historical
statements
including
among
things
statements
relating
company
expectations
regarding
future
financial
performance
backlog
sales
marketing
products
market
size
growth
timing
fda
filings
approvals
including
dmfs
anp
timing
product
launches
acquisitions
matters
related
pipeline
product
candidates
share
buyback
program
future
events
statements
historical
facts
rather
based
amphastar
historical
performance
current
expectations
estimates
projections
regarding
amphastar
business
operations
similar
related
factors
words
may
might
could
would
anticipate
predict
potential
continue
expect
intend
plan
project
believe
estimate
similar
related
expressions
used
identify
statements
however
statements
contain
words
place
undue
reliance
statements
involve
known
unknown
risks
uncertainties
assumptions
difficult
impossible
predict
cases
beyond
amphastar
control
actual
results
may
differ
materially
statements
result
number
factors
including
described
amphastar
filings
securities
exchange
commission
locate
reports
company
website
http
sec
website
amphastar
undertakes
obligation
revise
update
information
press
release
reflect
events
circumstances
future
even
new
information
becomes
available
subsequent
events
cause
amphastar
expectations
change
noted
products
trademarks
registered
trademarks
respective
owners
contact
information
amphastar
pharmaceuticals
bill
peters
chief
financial
officer
